SecBot SecBot
SC 13G ·Filed Nov 12, 2026

PPBT

PURPLE BIOTECH LTD.
NEUTRAL
Impact 3/10
Horizonweeks Processed4d 16h ago SEC0001493152-26-051281
Passive investor 5%+ stake
Actionable Insight • Neutral

Ayrton Capital's passive 9.99% warrant-based stake adds to existing similar positions by Intracoastal Capital and Susquehanna. Monitor for any conversion to SC 13D or exercise of warrants, which could signal a shift from passive to active intent.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.56
T+0 close · Nov 12, 2026 · via day close
Latest settled
+4.49%
T+1 · $1.63
Vs SPY
+4.85%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $1.56entry
  2. T+1 · 4d ago +4.49%α +4.85% · $1.63
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ayrton Capital LLC filed a new Schedule 13G disclosing beneficial ownership of 103,250 American Depositary Shares (each representing 2,000 ordinary shares) of Purple Biotech Ltd., representing 9.99% of outstanding common stock as of September 30, 2026. The shares are issuable upon exercise of warrants subject to a 9.99% beneficial ownership blocker. The filing certifies passive intent with no control-related purpose.

Key Financial Metrics

Stake
9.99%
Investor
Ayrton Capital LLC
Investor Type
hedge fund

Key Facts

  • Ayrton Capital LLC, along with Alto Opportunity Master Fund and Waqas Khatri, filed a new SC 13G disclosing a 9.99% beneficial ownership stake in Purple Biotech Ltd.
  • The stake consists of 103,250 shares of common stock issuable upon exercise of warrants, subject to a 9.99% beneficial ownership blocker.
  • The filing certifies passive intent under Rule 13d-1(b) with no purpose of changing or influencing control.
  • The percentage is based on 929,456 shares outstanding as of December 31, 2025, per the issuer's Form 20-F filed March 19, 2026.
  • Prior SC 13G/A filings by Intracoastal Capital LLC (also 9.99% warrant-based) and Susquehanna Securities were filed in August and May 2026.

Financial Impact

9.99% beneficial ownership via warrants; no cash value stated in filing

dilution

Risk Factors

  • Warrant exercise could increase share count and dilute existing holders
  • Multiple passive holders at the 9.99% blocker level may indicate coordinated interest; any future 13D conversion would be a material event

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0001493152-26-051281
Document: 0001493152-26-051281-index.html0001493152-26-051281
Document: 0001493152-26-051281.txt0001493152-26-051281

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026